Laser microdissection (LMD) and mass spectrometry (MS) is a new technique that consists of dissection of glomeruli, tryptic digestion of dissected material, analysis by MS and generation of a protein profile using different algorithms. The review focuses on the use of this methodology as an ancillary technique in a clinical laboratory for the diagnosis of kidney diseases.
INTRODUCTION
The pathology and diagnosis of kidney disease is based on examination of the kidney biopsy material by light microscopy, immunofluorescence microscopy and electron microscopy [1] . In addition, immunohistochemical staining of proteins has been used to identify a protein of interest. These techniques have resulted in unravelling the pathogenesis of many kidney diseases. However, given the inherent limitations of these targeted techniques, newer methods that could examine global protein expression to diagnose and understand the pathophysiology of the kidney disease in a clinical setting are required. Laser microdissection (LMD) combined with mass spectrometry (MS) based proteomics is a new diagnostic tool that enables analysis of global protein expression patterns in areas of interest, such as a glomerulus, interstitium and the tubules. Using this technique, the protein profile of diseased glomeruli can be compared with the protein profile of a normal glomerulus. In this review, we discuss the role and usefulness of LMD/MS in the diagnosis of various renal diseases.
BASIC METHODOLOGY
The methodology has been recently published [2,3,4 && ,5]. Briefly, glomeruli are identified on 6 or 10 mm thick sections of formalin-fixed paraffinembedded material. The sections are stained either with haematoxylin and eosin for easy identification of renal microanatomy such as the glomeruli or with Congo red for identification of amyloid deposits. In our setting, the glomeruli are laser microdissected using the Leica dissector (Leica DM 600 B; Leica Microsystems, Mannheim, Germany). Each microdissection is called a 'sample' and each microdissection contains an area of 60 000-100 000 mm 2 (60 000 collected for 10 mm thick section; 100 000 collected for 6 mm thick section) and this may involve four to six glomeruli depending on size (Fig. 1) . Typically, two to four samples are analysed for each case. The microdissected material is collected into 0.5 ml microcentrifuge tube caps containing 35 ml Tris/EDTA/0.002% Zwittergent buffer. Microdissected fragments are digested into tryptic peptides overnight and analysed by liquid chromatography electrospray tandem MS. MS raw data files are queried using three different algorithms (Sequest, Mascot and X!Tandem); the results are combined and assigned peptide and protein probability scores and displayed in Scaffold (Proteome Software Inc., Portland, Oregon, USA). For each sample, a list of proteins based on peptides identified by MS is generated. Peptide identifications are accepted if they could be established at greater than 90.0% probability as specified by the Peptide Prophet algorithm [6] [7] [8] . The MS data show spectra that match to a particular protein based on the amino acid sequence available in the database. Some of the peptides from different proteins can be common and be shared depending upon the homology of their amino acid sequence. On the other hand, unique peptides and spectra are distinctive to the particular protein. The 'Spectra' value indicates the total number of mass spectra collected on by MS and matched to the protein using the proteomics software. A higher number of mass spectra is indicative of greater abundance and will typically yield greater amino acid sequence coverage. A higher mass spectra value also indicates a higher confidence in the protein identification. Our clinical amyloid testing requires a minimum number of four spectra in all samples before the protein identification will be deemed clinically valid.
GLOMERULAR DISEASES WITH ORGANIZED DEPOSITS
LMD/MS has been useful in the diagnosis and understanding of glomerular diseases associated with organized deposits, including amyloidosis, fibrillary glomerulonephritis and immunotactoid glomerulopathy.
Amyloidosis
Amyloidosis is a disease characterized by extracellular accumulation of protein fibrils in various organs; the kidney is one of the most common organs involved [9] . The characteristic feature is a positive Congo-red stain wherein the amyloid deposits appear reddish-brown and show an KEY POINTS LMD/MS is used in the diagnosis and typing of amyloidosis, particularly where routine immunofluorescence and immunohistochemistry are equivocal. LMD/MS is used for diagnosis of the less common types of amyloidosis, such as LECT-2, fibrinogen-a, gelsolin, apolipoprotein A-I, II and IV, and transthyretin amyloidosis.
LMD/MS is used to confirm the presence of immune complexes, particularly monoclonal deposits, in the setting of immune complex mediated glomerulonephritis.
LMD/MS is used to confirm the presence of complement factors of the alternative pathway and terminal pathway, in the setting of complementmediated glomerulonephritis. apple-green birefringence under polarized light. The two common types of amyloidosis include immunoglobulin light-chain amyloidosis (AL amyloidosis) caused by deposition of immunoglobulin light chains and reactive secondary amyloidosis (AA amyloidosis) caused by deposition of acute phase reactant serum amyloid A protein. However, more than 25 types of amyloidosis are recognized including amyloidosis derived from a variety serum proteins such as apolipoprotein I, II and IV, gelsolin, leukocyte cell derived chemotaxin-2 (LECT2) and fibrinogen-a [10] . Accurate diagnosis and typing of amyloidosis is critical for the treatment and prognosis [11 & ]. Conventional light microscopy and immunofluorescence microscopy is generally adequate for the diagnosis of most cases of AL amyloidosis. Most laboratories use immunohistochemical methods for the diagnosis of AA amyloidosis, and increasingly for LECT2 amyloidosis. However, for the remainder of cases, most institutes use clinical surrogate markers such as serum studies and genetic tests that have low specificity and/or sensitivity to establish the cause. It is for this group of amyloidosis that LMD/MS has proved to be extremely useful.
The diagnosis of amyloidosis at the proteomic level using LMD/MS is based on the presence of large spectra numbers for the amyloidogenic protein, in addition to apolipoprotein E and serum amyloid P component (SAP) [4 && ]. Thus, in AL amyloidosis, large spectra numbers of immunoglobulin light chain constant regions along with apolipoprotein E and SAP are present. On the other hand, in LECT2 and fibrinogen-a amyloidosis, large spectra numbers of LECT2 and fibrinogen-a chain are present, respectively, along with apolipoprotein E and SAP.
The major advantage of LMD/MS over conventional methods of amyloid typing is that LMD/MS is a single test that can identify the amyloid protein in question versus testing the renal biopsy for individual amyloid proteins via immunohistochemistry or other ancillary studies [12] . In addition, LMD/MS is performed on paraffin block and has no special tissue requirements. It is often possible to identify the genetic variants of amyloidogenic proteins, such as variants of serum amyloid protein A or fibrinogen-a protein [13] . The common indications for LMD/MS studies in renal amyloidosis include confirmation of amyloid type, inadequate sample for immunofluorescence studies, difficult cases on routine renal biopsy studies such as heavy chain amyloidosis, and familial and hereditary amyloidosis [3, 10] . An example of LMD/MS results of representative cases of AA, apolipoprotein A-IV, fibrinogen-a, gelsolin, heavy chain amyloid, AL-kappa light chain, AL-lambda light chain, LECT2 and transthyretin amyloidosis are shown in Fig. 2 .
Fibrillary glomerulonephritis and immunotactoid glomerulopathy
In addition to amyloidosis, fibrillary deposits are also present in fibrillary glomerulonephritis [14] . The fibrils in fibrillary glomerulonephritis are usually polyclonal and stain for IgG, kappa and FIGURE 2. Representative mass spectrometry data of amyloidosis. Representative mass spectrometry data by spectral analyses from a case of reactive secondary amyloidosis (AA), apolipoprotein A-IV amyloidosis (ApoA-IV), fibrinogen-a amyloidosis (Afib), gelsolin amyloidosis (Agel), heavy chain amyloidosis (AH), AL kappa light chain amyloidosis (AL-kappa), AL lambda light chain amyloidosis (AL-lambda), LECT-2 amyloidosis (Alect2) and transthyretin amyloidosis (ATTR). The probability number (>95% is highlighted by green, 80-94% by yellow) indicates essentially the percentage homology between peptides detected in the specimens and the published amino acid sequences of their corresponding proteins. lambda light chains. The fibrils are similar to amyloidosis in that they are randomly arranged but are thicker and measure 10-30 nm in thickness.
The most important differentiating feature is that the fibrils in fibrillary glomerulonephritis are Congo-red negative. In spite of these differences, the presence of a heavy chain component, equivocal Congo-red staining, or the presence of a monoclonal gammopathy sometimes causes a diagnostic dilemma between amyloidosis and fibrillary glomerulonephritis. In such cases, LMD/MS is helpful in differentiating the two conditions. In fibrillary glomerulonephritis, large spectra of IgG1 chain C-region and apolipoprotein E are present, with no or very small spectra for SAP. On the other hand, amyloidosis shows large spectra of immunoglobulin light chain constant (C) region, SAP and apolipoprotein E. Typically, in amyloidosis the spectra ratio of apolipoprotein E to light chain is 2-3 : 1, whereas in fibrillary glomerulonephritis the ratio is often close to 1 : 1.
In immunotactoid glomerulopathy, the deposits have a microtubular structure that are often arranged in parallel arrays and measure 10-90 nm in diameter. The deposits are typically monoclonal and stain for IgG and kappa or lambda light chains, and are often associated with an underlying paraproteinemia. Although the pathologic findings are quite typical in immunotactoid glomerulopathy with the diagnosis resting on identification of the microtubular deposits, recent studies using LMD/MS have given insights into the development of fibrillary deposits in amyloidosis and fibrillary glomerulonephritis, and microtubular deposits in immunotactoid glomerulopathy. LMD/MS of the glomeruli suggests that it is the ratio of apolipoprotein E to the amyloidogenic protein/immunoglobulin that results in fibrillary versus microtubular deposits. Thus, in amyloidosis, very high spectra numbers of apolipoprotein E and moderate to high spectra numbers of light chains or other amyloidogenic proteins is associated with amyloid fibrils. In fibrillary glomerulonephritis, apolipoprotein E is present in moderate to low spectra numbers, and the ratio compared with immunoglobulin gamma-1 constant region is typically 1 : 1. On the contrary, in immunotactoid glomerulonephritis, apolipoprotein E is present in low spectra numbers, whereas the immunoglobulin gamma-1 constant region is present in high spectra numbers. Thus, the ratio of immunoglobulin and apolipoprotein E is reversed to 3 : 1. From these studies, it appears that apolipoprotein E (and the ratio to the amyloidogenic immunoglobulin protein) contributes to fibrillogenesis: high spectra numbers are associated with the thinner fibrils in amyloidosis, and smaller spectra numbers are associated with the thicker fibrils present in fibrillary glomerulonephritis (Fig. 3) [15 & ]. The absence of apolipoprotein E in deposits of cryoglobulinemic glomerulonephritis (that lack substructure) further suggests that apolipoprotein E is required for fibrillogenesis.
MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Membranoproliferative glomerulonephritis (MPGN) results from an inflammatory response to glomerular capillary wall deposition of immune complexes and complement factors or deposition complement factors alone [16] confirming the type of deposits in these conditions but have also been instrumental in elucidating the pathogenesis of these diseases. Immunofluorescence microscopy studies have variable sensitivity and specificity in identifying immune complex deposits and thereby can be inconclusive. Monoclonal gammopathy was noted in 41% of the patients with MPGN in one study [17] . Thus, accurate identification of monoclonal immunoglobulin is of paramount importance. The detection of monoclonal immunoglobulin can sometimes be difficult on routine immunofluorescence studies. In such cases, LMD/MS has been particularly useful in identifying the monoclonal immunoglobulin.
Membranoproliferative glomerulonephritis, immune complex mediated
A case is highlighted to illustrate this point: A 58-year-old asymptomatic woman with a history of longstanding hypertension presented with a preserved renal function, microscopic hematuria and 5 g/24 h of proteinuria. Renal biopsy was consistent with membranoproliferative pattern of injury. Immunofluorescence studies showed only staining for segmental IgM and C3, likely representing entrapment in segmentally scarred capillary tufts. However, electron microscopy showed many subendothelial, subepithelial and mesangial electron dense deposits. The evaluation was negative for any infectious causes or autoimmune disease; however, an IgG kappa monoclonal protein was identified in the serum at 0.4 mg/dl. Furthermore, serum immunoglobulin free light chain kappa to lambda ratio was elevated at 2.96. Bone marrow biopsy revealed 8% plasma cells, and there was no evidence of anemia, hypercalcemia or any lytic lesions. Thus, she was labelled as having an MGUS. Due to the discordance between serum monoclonal protein (IgG kappa) and immunofluorescence findings (segmental IgM, and no light chain restriction), it was unclear whether the patient's MPGN was related to the monoclonal gammopathy. LMD/MS studies were then performed that identified the deposits as IgG kappa, thus confirming that the MPGN was indeed due to deposition of IgG kappa (Fig. 4) [18] .
LMD/MS might be also useful in cases of light or heavy chain deposition disease wherein immunofluorescence microscopy results are sometimes equivocal. In such cases, there is marked mesangial expansion resulting in periodic acid-Schiff (PAS) and silver positive mesangial nodules that appear similar to diabetic mesangial nodules. The distinguishing feature is that the nodules of light/ heavy chain deposition are positive for the respective immunoglobulin light/heavy chain on immunofluorescence studies, whereas the diabetic nodules are negative. However, the immunofluorescence studies are equivocal in some cases of immunoglobulin light or heavy chain deposition disease and LMD/MS can confirm the presence of the immunoglobulin light/heavy chains.
Membranoproliferative glomerulonephritis, complement-mediated: dense deposit disease and C3 glomerulonephritis Dense deposit disease (DDD) and C3 glomerulonephritis are both complement debris diseases resulting from dysfunction of the alternative pathway of complement. They fall under the umbrella term 'C3 glomerulopathy' to reflect a common pathophysiology [19, 20] . Both DDD and C3GN often show a proliferative glomerulonephritis on light microscopy and bright C3 staining on immunofluorescence microscopy [21, 22] . They are differentiated from each other on the basis of electron microscopy findings that show dense osmiophilic deposits along the glomerular basement membranes and in the mesangium in DDD and distinct subendothelial and mesangial deposits (and occasional subepithelial and intramembranous deposits) in C3 glomerulonephritis. Although both conditions show bright C3 staining on immunofluorescence microscopy, the composition of the deposits are not known, and are a cause of speculation, particularly in DDD [2] . LMD/MS in both conditions showed accumulation of complement factors of the alternative pathway and terminal complement pathway (Fig. 5) . Thus, large spectra numbers of C3 and C9 were found in all cases of DDD and C3 glomerulonephritis. Smaller spectra numbers of C5, C6, C7 and C8 were also present. Complement regulating proteins such as vitronectin and clusterin were also present in large spectra numbers. In addition, large spectra numbers of complement FHR-1 and FHR-5 were present. There was little or no significant accumulation of complement factors of the classical complement pathway, such as C1, C2 or C4. In addition, there was little or no immunoglobulin present. There was also no Factor B present, indicating absence of C3 and C5 convertase in the glomeruli, suggesting that activation of alternative and terminal pathways occurs in the fluid phase rather than resulting from local disturbance of the alternative pathway. The presence of the TCC/soluble membrane attack complex in the deposits of DDD and C3 glomerulonephritis is an important factor that determines the effectiveness of the new anticomplement drug, eculizumab, in these conditions [23] [24] [25] . Eculizumab acts on the terminal pathway via inhibiting C5a. Thus, glomeruli of biopsy specimens of DDD and C3 glomerulonephritis for which MS shows large spectra numbers of the terminal complement pathway proteins are the cases that will likely respond to treatment with eculizumab.
To summarize, LMD/MS is useful in confirming the cause of proliferative glomerulonephritis, that is, immune complex mediated versus complement-mediated. With regard to immune complex MPGN, LMD/MS can detect the immune complex deposits that were negative or equivocal on immunofluorescence studies. With regard to complementmediated glomerulonephritis, LMD/MS can detect the components of the alternative and terminal complement pathways. Thus, therapy can be optimized on the basis of the immune complex or complement proteins deposited in the glomeruli.
NECROTIZING AND CRESCENTIC GLOMERULONEPHRITIS
Necrotizing and crescentic glomerulonephritis is the most severe form of renal injury. In the majority of cases, the pathologic process is due to injury resulting from circulating antiglomerular basement membrane (anti-GBM) antibodies, immune complex deposition or pauci-immune causes. These are often classified as type I, type II and type III, respectively [26] . Immune complex mediated glomerulonephritis with crescents includes entities such as lupus nephritis, IgA nephropathy and so on. Pauci-immune necrotizing and crescentic glomerulonephritis is often associated with antineutrophil cytoplasmic antibodies (ANCAs) [27] . However, a small proportion of pauci-immune necrotizing and crescentic glomerulonephritis cases are ANCA-negative. In a recent study of one such case, LMD/MS showed large spectra numbers for fibrinogen, C3 and TCC factors in the glomeruli along with the absence of any immunoglobulin deposition. The findings suggested activation of the alternative pathway of complement [28] . Indeed, evaluation of the alternative pathway revealed a complement factor H mutation that was not previously reported. On the basis of this report, it was suggested that the ANCA-negative pauci-immune crescentic and necrotizing glomerulonephritis result from abnormalities in the alternative pathway of complement. LMD/MS studies of ANCA-negative and ANCA-positive pauci-immune crescentic and necrotizing glomerulonephritis are underway to determine whether a role of the alternative pathway can be identified in the ANCA-negative pauci-immune crescentic and necrotizing glomerulonephritis.
FUTURE STUDIES
There is a potential for use of LMD/MS in the study of many glomerular and tubulointerstitial diseases. For example, in the setting of nephrotic syndrome, LMD/MS can be used to identify the proteins in minimal change disease and focal segmental glomerulosclerosis to determine whether unique protein profiles are present in these states. In the setting of infection-associated tubulointerstitial nephritis, LMD/MS can be used to identify specific viral, fungal or bacterial proteins.
CONCLUSION
LMD/MS is a new technique that shows great promise for the diagnosis and understanding of kidney diseases. It is currently routinely used as an ancillary test for the diagnosis and typing of amyloidosis. It is also used as an ancillary test for the diagnosis of glomerulonephritis resulting from immune complex deposition and/or complement deposition.
